EUROPEAN MEDTECH


12/12/17 -"Just how long can a good thing last? Not unto eternity, if fundamentals have their say. Riding on the coattails of its first cousin, pharma (and thriving on its miseries), the recent rally in Med-tech seems to have run its course. This study captures why the sector makes for slim pickings at current levels and why a slowdown...or more accurately…a correction... is imminent. Our Lead Analyst Jyoti Prakash has published her latest note entitled " EUROPEAN MEDTECH: A correction is imminent". "

Pages
30
Language
English
Published on
12/12/17

EXECUTIVE SUMMARY

Just how long can a good thing last? Not unto eternity, if fundamentals have their say. Riding on the coattails of its first cousin, pharma (and thriving on its miseries), the recent rally in Med-tech seems to have run its course.
This study captures why the sector makes for slim pickings at current levels and why a slowdown...or more accurately…a correction... is imminent.
Our Lead Analyst Jyoti Prakash has published her latest note entitled " EUROPEAN MEDTECH: A correction is imminent".

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO